Quest for the right Drug
עמוד הבית / אבטור 2.5
אבטור 2.5 EVETOR 2.5 (EVEROLIMUS)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
מידע מעלון לרופא
מינונים
Posology
התוויות
Indications
תופעות לוואי
Adverse reactions
התוויות נגד
Contraindications
אינטראקציות
Interactions
מינון יתר
Overdose
הריון/הנקה
Pregnancy & Lactation
אוכלוסיות מיוחדות
Special populations
תכונות פרמקולוגיות
Pharmacological properties
מידע רוקחי
Pharmaceutical particulars
אזהרת שימוש
Special Warning
עלון לרופא לא נמצא
Physicians Leaflet
התוויה
Evetor is indicated for:- Treatment of patients with SEGA associated with tuberous sclerosis Complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Evetor is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated. - Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. The safety and effectiveness of EVETOR in the treatment of patients with carcinoid tumors have not been established. - Treatment of hormone receptor – positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non – steroidal aromatase inhibitor. - Treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of Evetor in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. - Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.- Treatment of unresectable, locally advanced or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף
